» Articles » PMID: 18382647

An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus

Abstract

Background: In summer 2003, a respiratory outbreak was investigated in British Columbia, during which nucleic acid tests and serology unexpectedly indicated reactivity for severe acute respiratory syndrome coronavirus (SARS-CoV).

Methods: Cases at a care facility were epidemiologically characterized and sequentially investigated for conventional agents of respiratory infection, SARS-CoV and other human CoVs. Serological cross-reactivity between SARS-CoV and human CoV-OC43 (HCoV-OC43) was investigated by peptide spot assay.

Results: Ninety-five of 142 residents (67%) and 53 of 160 staff members (33%) experienced symptoms of respiratory infection. Symptomatic residents experienced cough (66%), fever (21%) and pneumonia (12%). Eight residents died, six with pneumonia. No staff members developed pneumonia. Findings on reverse transcriptase-polymerase chain reaction assays for SARS-CoV at a national reference laboratory were suspected to represent false positives, but this was confounded by concurrent identification of antibody to N protein on serology. Subsequent testing by reverse transcriptase-polymerase chain reaction confirmed HCoV-OC43 infection. Convalescent serology ruled out SARS. Notably, sera demonstrated cross-reactivity against nucleocapsid peptide sequences common to HCoV-OC43 and SARS-CoV.

Conclusions: These findings underscore the virulence of human CoV-OC43 in elderly populations and confirm that cross-reactivity to antibody against nucleocapsid proteins from these viruses must be considered when interpreting serological tests for SARS-CoV.

Citing Articles

Aerosol transmission of human pathogens: From miasmata to modern viral pandemics and their preservation potential in the Anthropocene record.

Moreno T, Gibbons W Geosci Front. 2024; 13(6):101282.

PMID: 38620922 PMC: 8356732. DOI: 10.1016/j.gsf.2021.101282.


Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4).

Kaur R, Tada T, Landau N mBio. 2023; 14(4):e0109023.

PMID: 37382452 PMC: 10470548. DOI: 10.1128/mbio.01090-23.


SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.

Bloch E, Kyeyune D, White J, Ddungu H, Ashokkumar S, Habtehyimer F Transfusion. 2023; 63(7):1354-1365.

PMID: 37255467 PMC: 10525030. DOI: 10.1111/trf.17449.


Human Coronavirus OC43 as a Low-Risk Model to Study COVID-19.

Kim M, Lee C Viruses. 2023; 15(2).

PMID: 36851792 PMC: 9965565. DOI: 10.3390/v15020578.


Evaluating the Virology and Evolution of Seasonal Human Coronaviruses Associated with the Common Cold in the COVID-19 Era.

Harrison C, Doster J, Landwehr E, Kumar N, White E, Beachboard D Microorganisms. 2023; 11(2).

PMID: 36838410 PMC: 9961755. DOI: 10.3390/microorganisms11020445.


References
1.
Skowronski D, Petric M, Daly P, Parker R, Bryce E, Doyle P . Coordinated response to SARS, Vancouver, Canada. Emerg Infect Dis. 2006; 12(1):155-8. PMC: 3291383. DOI: 10.3201/eid1201.050327. View

2.
Birch C, Clothier H, Seccull A, Tran T, Catton M, Lambert S . Human coronavirus OC43 causes influenza-like illness in residents and staff of aged-care facilities in Melbourne, Australia. Epidemiol Infect. 2005; 133(2):273-7. PMC: 2870246. DOI: 10.1017/s0950268804003346. View

3.
Riley S, Fraser C, Donnelly C, Ghani A, Abu-Raddad L, Hedley A . Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science. 2003; 300(5627):1961-6. DOI: 10.1126/science.1086478. View

4.
Atmar R, Glezen W, Greenberg S . Spectrum of clinical illness in hospitalized patients with "common cold" virus infections. Clin Infect Dis. 2000; 31(1):96-100. PMC: 7109925. DOI: 10.1086/313937. View

5.
Poutanen S, Low D, Henry B, Finkelstein S, Rose D, Green K . Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003; 348(20):1995-2005. DOI: 10.1056/NEJMoa030634. View